Your shopping cart is currently empty

AKOS-22 is a potent mitochondrial protein VDAC1 (voltage-dependent anion channel 1) inhibitor (Kd=15.4 μM). AKOS-22 protects against mitochondrial dysfunction[1]. AKOS-22 interacts with VDAC1 and inhibiting both VDAC1 oligomerization and apoptosis.


| Description | AKOS-22 is a potent mitochondrial protein VDAC1 (voltage-dependent anion channel 1) inhibitor (Kd=15.4 μM). AKOS-22 protects against mitochondrial dysfunction[1]. AKOS-22 interacts with VDAC1 and inhibiting both VDAC1 oligomerization and apoptosis. |
| Targets&IC50 | VDAC1:(kd)15.4 μM |
| In vitro | AKOS-22 inhibits selenite-induced VDAC1 oligomerization, Cyto c release and apoptosis in HEK-293 cells (IC50=3.3-3.6 μM), and which prevents the elevation of [Ca2+]I associated with apoptosis induction, and thus Ca2+ accumulation by the mitochondria[1]. AKOS-22 (5-20 μM; 2 hours) inhibits both VDAC1 oligomerization and apoptosis in a concentration-dependent manner (IC50=7.5 μM)[1]. AKOS-22 (30 μM, 2 h) inhibits cisplatin-induced VDAC1 oligomerization and apoptosis in neuroblastoma cell line SH-SY5Y. |
| Molecular Weight | 467.87 |
| Formula | C22H21ClF3N3O3 |
| Cas No. | 878983-38-1 |
| Smiles | O=C1N(C(=O)CC1N2CCC(NC3=CC=C(OC(F)(F)F)C=C3)CC2)C4=CC=C(Cl)C=C4 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.